More Proof of the damage of Anti-Depressants

THIS VIDEO IS A MUST SEE -
The beginning is dramatic and emotional, but the end is very educational.
It proves that everything I've been saying about these anti-depressants is true and "real". Coming from actual victims and professionals. Please click on the link.
http://www.thesaveproject.com/
 
Camille Milke, Eternal "Mommy" of Sarina Angel
Yesterday, Today, Tomorrow and Forever........
My Beautiful Baby Girl, 1/26/86 - 10/28/07, 21 years 9 months 3 days
COPES Foundation (Coalition Of Parents Enduring Suicide)
Founder and President, Main - 505-269-2286, Fax - 505-213-0999
www.COPESFoundation.com
www.ILoveYouSarina21.last-memories.com

Wed Nov 12, 2008 7:33 pm

We have received a request from a German TV crew who is doing a special on
Lilly's newer ADHD medication, Stratera. These investigative reporters from
Germany are doing a 45 minute piece and looking for experiences of tragedy /
suicide or severe adverse reactions in children treated for ADHD with this
drug. I know we have had reports, but I do not keep close track anymore of
which
drug is involved after so many cases because all these drugs work basically
the same way. An antidepressant is an antidepressant no matter what you call
it or what you prescribe it for or how you explain its supposed uniqueness. So
if you or someone you know has been through a Strattera-induced nightmare
and would be willing to help get some exposure of this in the press, please
get in touch with me so that I can put you in touch the reporters.



Once you read the following article on Strattera deaths you will see how
very important it is to get information about this drug out to the public -
especially throughout the UK and Europe. What is going on here IS CRIMINAL!!
And
here is just one example out of the article below that is full of data on how
the government agency in the UK who oversees these drugs is ignoring
critical information - even fatalities, and doing NOTHING but making excuses
for
their own behavior:

MHRA has for almost three years been in possession of data showing that
Strattera in many cases actually can cause or worsen the “condition� it is
claimed to alleviate. More than 700 reports were submitted to the manufacturer,
Eli Lilly, about Strattera inducing “psychomotor hyperactivity�. Lilly
called
this an exacerbation of the “underlying ADHD�. If we would apply this to
the
area of real medicine and to diabetes we could say that the patient got a
diabetes medication with resulting heavy increase in blood sugar level. Such a
medication would probably be withdrawn very fast from the market. But the
MHRA has not yet, after three years, succeeded to get even a bad quality review
of these cases done – not even from the manufacturer.


Do read the rest of the information because it is clearly eye opening!! This
newer ADHD drug, Strattera, which is really an SSRI antidepressant, is
getting away with murder right under everyone's noses. So definitely if you
know
someone who is willing to talk to this news crew about their experience with
this drug, please do let me know ASAP.

Thank you,


Ann Blake-Tracy, PhD, Executive Director,
International Coalition for Drug Awareness
_www.drugawareness.org_ (http://www.drugawareness.org/) &
_www.ssristories.org_ (http://www.ssristories.org/)
Author of Prozac: Panacea or Pandora? - Our
Serotonin Nightmare & the audio, Help! I Can't
Get Off My Antidepressant!!! (800-280-0730)

E-mail: _atracyphd1@..._ (mailto:atracyphd1@...)




_http://www.newmediaexplorer.org/sepp/2008/10/20/strattera_adverse_effects_uk_
medicines_agency_refuses_to_act.htm#_
(http://www.newmediaexplorer.org/sepp/2008/10/20/strattera_adverse_effects_uk_me\
dicines_agency_refuses_to_act.htm#)


October 20, 2008
_Print this article_
(http://www.newmediaexplorer.org/sepp/2008/10/20/strattera_adverse_effects_uk_me\
dicines_agency_refuses_to_act.htm#)


Strattera adverse effects: UK Medicines Agency refuses to act
By Sepp Hasslberger


Categories
_Pharma_ (http://www.newmediaexplorer.org/sepp/pharma.htm)

Janne Larsson, an investigator and reporter in Sweden, has obtained
information about adverse event reports on Eli Lilly's ADHD drug Strattera,
using the
Swedish freedom of information laws. The data, coming from both the FDA's
adverse reaction database and from reports to the UK's Medicines agency, shows
numerous adverse effects and scores of deaths by suicide.
Yet the agency, even after repeated prodding by Larsson to initiate action,
has refused to budge or even acknowledge that there is a problem. MHRA
apparently accepts the drug's producer Eli Lilly's data rather than its own and
the
FDA's adverse event reports.


Image credit: _Monheit Law_
(http://www.monheit.com/strattera/contact_lawyer.asp)

Larsson says: An investigation of MHRA’s handling of the harmful effects of
the ADHD drug Strattera has proven the following:


MHRA has ignored data about instances of death among children in connection
with Strattera treatment. At least 41 children have died. The agency has not
investigated the reported cases and does not even have a compiled summary of
cases with fatal outcome. Further the agency has allowed the manufacturer Eli
Lilly to give false information about the number of fatal cases and has
taken no action against the company once the false information was revealed.

MHRA has for almost three years been in possession of data proving that
Strattera can cause agitation, mania and psychotic reactions with
hallucinations
among children. Yet no warning has been issued to doctors and parents. The
agency has withheld these disastrous consequences despite clear evidence. Due
to bureaucratic procedures no warnings have been issued even if Eli Lilly reluc
tanly conceded to include these harmful reactions in its information to the
public almost a year ago.

MHRA has for almost three years been in possession of data showing that
Strattera in many cases actually can cause or worsen the “condition� it is
claimed to alleviate. More than 700 reports were submitted to the manufacturer,
Eli Lilly, about Strattera inducing “psychomotor hyperactivity�. Lilly
called
this an exacerbation of the “underlying ADHD�. If we would apply this to
the
area of real medicine and to diabetes we could say that the patient got a
diabetes medication with resulting heavy increase in blood sugar level. Such a
medication would probably be withdrawn very fast from the market. But the
MHRA has not yet, after three years, succeeded to get even a bad quality review
of these cases done – not even from the manufacturer.
The background data for these conclusions can be found in the following text
and in the linked documents. When reading the data below please remember the
promise from the MHRA: “…we take any necessary action to protect the public
promptly if there is a problem.�_MHRA, About us_
(http://www.mhra.gov.uk/Aboutus/index.htm) [1]


Note that the linked documents (within letters described below) in most
cases could not be obtained in UK where the issuance of them would be deemed as
prejudicing “the ability of the Assessory body to offer impartial advice�
and
where the MHRA wants “to allow marketing authorisation holders the chance to
respond to regulatory action and make commercial decisions before data are
in the public domain.� (MHRA, e-mail about FOIA-request, 29th September,
2006). However the documents could be obtained in Sweden, even if the MHRA has
tried to stop the issuance of them by implying that publication could threaten
the relations between Sweden and UK.
Deaths among children in connection with Strattera treatment

In May I submitted detailed data about cases of Strattera death to the MHRA.
1st October I finally got an answer from the Scientific Assessor of the
Vigilance and Risk Management of Medicines (VRMM). 7th October I got an answer
from Professor Kent Woods, CEO of the MHRA, referring to the letter sent by the
Scientific Assessor.

My data about Strattera deaths can be found _in the letter_
(http://jannel.se/Strattera.death2.pdf) Strattera: Eli Lilly gave false
information about
deaths from Strattera treatment – a request for full investigation from 15th
May. [2]
The answer from the Scientific Assessor shows that MHRA is continuing to
ignore data about instances of death among children and adults in connection
with Strattera treatment. Despite limited resources and having to rely on data
released by reluctant medical agencies I had been able to produce a summary of
reported cases of Strattera death. That’s much more than the MHRA, with its
immense resources, had been able to do.

The agency was provided with specific data about instances of death forming
an excellent starting point for a full investigation. But instead of using
the data the MHRA used its energy to explain why it is impossible to
investigate these cases further, and in doing so presents some remarkable
comments.

The Scientific Assessor states _in the letter 1st October_
(http://jannel.se/Reply.from%20MHRA.Assessor.October.pdf) [3]:


“… in order to calculate the total number of reports with a fatal outcome
it is not simply a case of adding up reports with a fatal outcome mentioned
in our assessment reports of the PSURs [Periodic Safety Update Reports] and
those available on the FDA website as these different sources may contain
duplicate information.� [Emphasis added.]


I fully agree and it takes only a casual reading of my letter from 15th May
to find out that much care has been taken to exclude possible duplicates. It
is quite easy to see that the data presented about fatal cases in my letter
is NOT “simply a case of adding up reports with a fatal outcome�. The only
way to come to another conclusion would be not to look in the first place and
it is a condemnation of the effectiveness of the agency to state the following
in the letter:


“We have looked at the data you have sent us to see if they can add insight
to the statutory sources of data we have received and do not think that they
are of benefit as we cannot verify their source or accuracy.� (p. 3)
[Emphasis added.]

I must add to all the data provided in my letter 15th May that the “source�
of the information about fatal cases is FDA’s Medwatch system and the PSURs
(submitted directly to the MHRA). I must make it clear that is very easy for
a lay person to find out that almost all reports about fatal outcome from
Strattera treatment submitted to the FDA came from Eli Lilly!

Thus the “source� of the information about fatal cases was in most of the
cases the manufacturer itself – Eli Lilly. And yet the MHRA has not been able
to verify the “source or accuracy� of the information. The MHRA Scientific
Assessor states in the letter: “The sources of data that regulators use such
as company data, spontaneous adverse reaction reports and literature are set
out in European and national law.�

My FOIA request earlier this year to get a compilation of fatal cases in
connection with Strattera treatment was answered 12th August:

That’s very good and now we know that the data I submitted to the MHRA about
all fatal cases from Strattera treatment – in the absolute majority of cases
– were known by and reported via the manufacturer Eli Lilly.
“The MHRA holds no data other than that previously released to you [the
misleading data from Eli Lilly in November 2007, see my letter from 15th May
for
more data] which was the data provided by the company. If you have any
questions about FDA data or the data provided by the company, you should
contact
those organisations.�


In other words the MHRA didn’t have a compiled summary of cases with fatal
outcome in August – and the agency has not to this point been able to compile
such a summary.

As the agency has not been capable of getting the data – or not even been
capable of using the specific data submitted for its use in a full
investigation – NO action is taken despite the many verified deaths among
children in
connection with Strattera treatment. This disregard for the safety of children
is a scandal which should lead to a full formal investigation by the
Department of Health.


Drug induced agitation, mania and psychosis with hallucinations

I’ve been contacted by parents asking if Strattera can induce mania and
psychosis with hallucinations. Their children have had such symptoms. The
parents
have not found any warnings about it and their children’s doctors don’t
think that the symptoms are caused by the drug. The parents were desperate.

However the MHRA has known for almost three years that Strattera can cause
agitation, mania and psychotic reactions with hallucinations among children,
but has refused to issue warnings about it.

The Scientific Assessor from the MHRA _in the letter of 1st October_
(http://jannel.se/Reply.from%20MHRA.Assessor.October.pdf) [3] now confirms my
earlier
arguments that the agency had knowledge about these effects a long time ago:


“… following an initial request in the assessment report for the Periodic
Safety Update for the period (dates 27-05-2005 to 26-11-2005) we asked Eli
Lilly for more information to enable us to review this issue in more detail.�
(p. 2)


This means that in the period ending 26th November, 2005 – at the time when
Strattera was approved only in UK and four other European countries, but not
in the 22 additional European countries where it is now approved – Eli Lilly
and the MHRA had knowledge about these disastrous effects in children taking
Strattera. But neither the MHRA nor Eli Lilly told anything about it and
Strattera was approved in 20 additional European countries in April 2006.
Image credit: _Wikimedia Commons_
(http://commons.wikimedia.org/wiki/Image:Strattera_atomoxetin.jpg)

Professor Kent Woods, CEO of the MHRA seems to be very misinformed by his
staff when answering about Strattera in a recent _letter of 7th October, 2008_
(http://jannel.se/answer.kent.woods.pdf) . In the letter Professor Woods
states [4]:


“The MHRA is committed to ensuring that all safety concerns are subject to
robust scientific assessment and the best possible regulatory action is taken
in a timely manner. We strive to maintain the highest standards of work and
review our practices to ensure these standards are maintained or improved
upon where necessary.� (p. 1)


In their 3rd March, 2006 report Psychiatric Adverse Events Associated with
Drug Treatment of ADHD: Review of Postmarketing Safety Data [5], the FDA
stated that there was “compelling evidence for a likely causal association
between
… [Strattera/amphetamine drugs] and treatment emergent onset of signs and/or
symptoms of psychosis or mania, notably hallucinations, in some patients.�
(p. 17) 360 reports about the drug inducing these effects had been received
up to June 2005.

From this FDA report the MHRA had knowledge about the “compelling evidence�
for Strattera causing these effects on or about 3rd March, 2006 – but did
nothing.

In August the same year (2006) the MHRA requested the same data set from Eli
Lilly that was submitted to the FDA and which formed the basis of the FDA
report for Strattera. The data was sent to the MHRA some days later. But the
agency then decided not to do anything with the information. Instead it was
decided that Eli Lilly – the manufacturer – should do an analysis of the
data
and submit its conclusions to the agency.

Professor Kent Woods says in his letter: “An important aspect to this [‘
robust scientific assessment’, ‘highest standards’] is ensuring that data
from
all available sources have been considered…�

This may be true in some other area but it is definitely not true for the
safety work around Strattera. A very good example of this is the complete
rejection of the “robust scientific assessment� of Strattera in the FDA
report.
Answering the question why the agency did not use the “compelling evidence�
for harm in the FDA report _an official at the MHRA declared in a letter_
(http://jannel.se/mhraanswer.pdf) [6]:

“Changes to European product information are based on assessment by EU
regulators, agreement between member states and in line with legal requirements
about product information, not on conclusions of FDA assessors.� (25th May,
2007) [Emphasis added.]

Responsible officials at the MHRA had instead decided to rely completely on
the analysis of the manufacturer of the drug – Eli Lilly. (In an article in
the Daily Mail this summer, Andrew Herxheimer, editor of the Drug and
Therapeutics Bulletin, and emeritus fellow of the Cochrane Centre commented:
“Asking
a drug company to review its own product is crazy, but it goes on quite a lot.
�) [7]

At the end of 2007/beginning 2008 Eli Lilly submitted its review of
Strattera induced agitation, mania and psychosis with hallucinations to the
MHRA. It
was a complete whitewash.

In summary: FDA was very clear about the psychosis-inducing effects of
Strattera; the MHRA did not listen. Instead the MHRA turned to the
manufacturer.
Eli Lilly tried to explain away all the bad results found in its review. For
the full history about MHRA’s failure in this area and for a comparison of
the
FDA report with the Lilly report, please see the following letter: _The
ADHD drug Strattera – actions needed now_
(http://jannel.se/letter.mhra.strattera.jan08.pdf) [8] from January 2008, and
the letter _The ADHD drug Strattera –
an analysis of reports of drug induced mania, psychosis and hallucinations_
(http://jannel.se/strattera.mhra.March.08.pdf) [9] from March 2008.

In the letter from March [9] Eli Lilly’s whitewash report for the period up
to November 2007 is presented. At the end of that report Lilly says [10]: “
Nevertheless, Lilly will consider adding language regarding psychotic symptoms
including hallucinations� to its product information sheet. (p. 1279)


Larsson - _Suicides & Psychiatric Drugs_
(http://www.newmediaexplorer.org/sepp/suicide.psychiatricdrugs.pdf)

And so we come to October 2008 and the letters from Professor Kent Woods and
from the Scientific Assessor for Strattera. We are “reassured that the MHRA
is acting … to ensure that Strattera is used … as safely as possible�,
that “
all safety concerns are subject to robust scientific assessment and the best
possible regulatory action�, that “any new safety signals are evaluated in
an independent, scientifically robust manner� (Woods); we are told that “
discussions between European Member States and Eli Lilly are ongoing to agree
on the most appropriate information to be included in the product information
for patients and prescribers�; we are told to be patient, to understand that
it takes time from the point where “updates have been agreed for inclusion in
the product information� to the point where these will “appear in the packs
in the market place due to movement of stock in the supply chain�, and that
the appearances are estimated to be “within the next 6 months� (Scientific
Assessor).

It is probably hard to find a more obvious violation of the promise “… we
take any necessary action to protect the public promptly if there is a
problem�
than the case described above. The worried parents still have no answers if
Strattera can induce the symptoms they find in their children. And the MHRA
knew about it three years ago – but withheld the data. This should be
included in the investigation of the agency by the Department of Health.


Strattera causing “hyperactivity� – the condition it was supposed to
alleviate

In my earlier letter to the Department of Health (29th August) I took up the
data about the “700 forgotten cases of hyperactivity�. I referred to my
_letter 2nd January to the MHRA_
(http://jannel.se/letter.mhra.strattera.jan08.pdf) [8] and gave data about the
fact that Eli Lilly had withheld sensitive
information and classified harmful effects as an “exacerbation of the
underlying ADHD�.

The logical solution would have been for the MHRA to request all data about
this security risk, followed by an independent review of the data. But this
was not done – and as expected nothing is still done. MHRA asked Lilly for an
explanation about this “signal� stemming from Periodic Safety Update Report
5 (dates 27-05-2005 to 26-11-2005) but got no answer. Three years later the
Scientific Assessor from the MHRA writes in the letter from 1st October:


“The information submitted by the MAH [Market Authorization Holder] has been
evaluated and the MAH will be requested to provide further detailed
information within the next 2 months to ensure the issue has been investigated
in a
thorough and scientific manner.� (p. 2) [3]


The MHRA got this “safety signal� almost three years ago – and is still
in
the process of getting some sensible answers from Eli Lilly.

------------

I again request the Department of Health to take action. This does not
concern “only� the children in UK; it concerns the children in the whole of
Europe, indeed it concerns all the children of the world.

The failure of the agency will also mean that psychiatrists within The
Guideline Development Group in NICE can push through more “treatment� with
Strattera and other ADHD drugs. The MHRA is withholding the clear evidence for
harmful effects and the psychiatrists with close relations to the manufacturers
of the drugs can unimpeded recommend these “medicines� to unsuspecting
doctors and parents.

The answers given by Professor Kent Woods and the Scientific Assessor did
not in any way handle my concerns. On the contrary, they finally proved that a
full formal investigation of the matters raised above is needed.

Yours sincerely,

Janne Larsson

Reporter - investigating psychiatry
Snöbollsgränd 22
129 45 Hägersten
Sweden
_janne.olov.larsson@..._ (mailto:janne.olov.larsson@...)


[1] MHRA, About us, _http://www.mhra.gov.uk_ (http://www.mhra.gov.uk/)
[2] Larsson, Strattera: Eli Lilly gave false information about deaths from
Strattera treatment – a request for full investigation, May 15, 2008,
_http://jannel.se/Strattera.death2.pdf_ (http://jannel.se/Strattera.death2.pdf)
[3] MHRA, Re: letter of 9th September 2008 to “Assessor responsible for
Strattera�, October 1, 2008,
_http://jannel.se/Reply.from%20MHRA.Assessor.October.pdf_
(http://jannel.se/Reply.from%20MHRA.Assessor.October.pdf)
[4] MHRA, Re: Open letter to Pr. Kent Woods (10th August 2008), October 7,
2008
_http://jannel.se/answer.kent.woods.pdf_
(http://jannel.se/answer.kent.woods.pdf)
[5] FDA, Psychiatric Adverse Events Associated with Drug Treatment of ADHD:
Review of Postmarketing Safety Data, released March 3, 2006.
_http://www.fda.gov/ohrms/dockets_
(http://www.fda.gov/ohrms/dockets/AC/06/briefing/2006-4210b_11_01_AdverseEvents.\
pdf)
[6] MHRA, answer FOI request, May 25, 2007,
_http://jannel.se/mhraanswer.pdf_ (http://jannel.se/mhraanswer.pdf)
[7] Daily Mail, Heart attacks and suicides... yet the dangers were all kept
so quiet. So how CAN you trust your medicine? July 7, 2008,
_http://www.dailymail.co.uk/_
(http://www.dailymail.co.uk/health/article-1033132/Side-effects-include-suicide-\
heart-attacks-So-prescribed-drugs.html)
[8] Larsson, The ADHD drug Strattera – actions needed now, January 2, 2008,
_http://jannel.se/letter.mhra.strattera.jan08.pdf_
(http://jannel.se/letter.mhra.strattera.jan08.pdf)
[9] Larsson, The ADHD drug Strattera – an analysis of reports of drug
induced mania, psychosis and hallucinations, March 9, 2008,
_http://jannel.se/strattera.mhra.March.08.pdf_
(http://jannel.se/strattera.mhra.March.08.pdf)
[10] Eli Lilly, Cumulative review of Spontaneous Case Reports of Mania,
Psychotic Disorders, Hallucinations, and Agitation, Appendix 16 to Periodic
Safety Report 9 for Strattera, 2008,
_http://jannel.se/Lilly_psychosis_strattera.pdf_
(http://jannel.se/Lilly_psychosis_strattera.pdf)

See also:

_Doctors told to curb use of Ritalin in hyperactive children_
(http://www.timesonline.co.uk/tol/news/uk/science/article4813727.ece)
_Children's suicide attempts raise concerns about ADHD medication_
(http://www.theglobeandmail.com/servlet/story/RTGAM.20080703.wadhd03/BNStory/spe\
cialScie
nceandHealth/home)
_The ADHD drug Strattera: Lilly to issue warnings about psychosis,
hallucinations, mania and agitation_ (http://jannel.se/strattera.psychosis.doc)
_Strattera side effects_ (http://www.bonkersinstitute.org/stratteraffex.html)

_Strattera - 10,988 adverse "psychiatric reactions" reported in less than
three years_ (http://www.24-7pressrelease.com/view_press_release.php?rID=16662)
_Attention Deficit Hyperactivity Disorder? No, they're just naughty, say
experts_
(http://www.dailymail.co.uk/news/article-1031436/Attention-Deficit-Hyperactivity\
-Disorder-No-theyre-just-naughty-say-experts.html#)

____________________________________
posted by Sepp Hasslberger on Monday October 20 2008

Wed Nov 12, 2008 7:26 pm

 "Paul Deyoub, a forensic psychologist with the Arkansas State Hospital in
Little Rock, testified for the state that he didn’t believe Basham was
delirious when he killed his wife.

"He said he didn’t believe Basham’s contention that he didn’t remember
anything about the killing, and that his first memory that day was waking up in
the hospital. He said nearly all defendants charged with domestic homicide
that he has evaluated claim to have no memory or some loss of memory of the
crime."


Well Mr. Forensic Psychologist just for your information (which I am sure
drug companies have paid enough to your institution of higher learning to
assure you never learn), the reason that " . . . nearly all defendants charged
with domestic homicide [that you have] evaluated claim to have no memory or
some
loss of memory of the crime" is because the large majority of those
defendants charged with domestic homicide are on SSRI or SNRI antidepressants
which
affect memory so adversely that "amnesia" is listed as a frequent side effect.
WAKE UP!!! If they cannot even remember who they are, how can they remember
what happened?!!!

And if this case was prosecuted by the same prosecutor I went up against in
Fayetteville a few years ago, who could not make one statement without first
reading it from the SSRI Prosecutor's How to Manual, it is no wonder the
courts' time is still being wasted prosecuting such cases when they should be
immediately dismissed and apologies and settlements issued directly from the
drug manufacturers to these families! How very tragic for this poor old man and
his family!!!

[The SSRI Prosecutor's manual is distributed by the drug manufacturers in
criminal cases to make sure that anyone who commits a crime, while under the
influence of their drugs, goes immediately to jail . Why? So that their drugs
remain "innocent" and therefore lucrative because who would want to use a drug
that a court has just said produced a suicide or murder or other violent
crime? Is providing such a manual illegal? No, but probably should be. Is it
unethical? Without a doubt!!!!

But it was obvious to me when testifying in these cases that this manual
existed due to prosecutors asking the same questions of me, almost word for
word
in every case, no matter which SSRI was involved or where in the country the
case was tried. So, while working as the defense attorney on Christopher
Pittman's case, Andy Vickery asked for the manual as evidence and got a copy
for
us. If anyone would like to waste their time reading it let me know and I
will gladly send you a copy.]


Now back to this elderly man's case:

As you read through the next two paragraphs understand why I gasp when I
hear that this man was given an SSRI while suffering from anxiety, pneumonia
and
sleep apnea. You see, anything that increases serotonin - as the SSRI
antidepressants are designed to do and all antidepressants do - shuts down the
lungs thereby cutting off oxygen to the brain. This is how these drugs produce
brain damage, the cutting off of the oxygen supply.

[If you would like to test out this idea on your own, do what I do. Every
time you see someone who is not elderly, but generally is overweight and is
carrying around an oxygen tank, ask them which antidepressant they have been on
and how long. Then explain to them that the main function of serotonin is the
constriction of smooth muscle tissue which includes the lungs and bronchial
tubes [and all major organs] which is why they now need oxygen. And then give
them our website because they are going to want to know what else these
drugs have done to their health. But always stress that abrupt or rapid
discontinuation of the drug/drugs is very dangerous.]

Paragraph 4 reads: "Ross testified that in an attempt to explain how
Basham, who never had a reputation for violence and always got along with his
wife,
could have committed such a bizarre act, she concluded that Basham suffered
from delirium."

Paragraph 7 reads: "Ross pointed out that Autry Basham had pneumonia, took
the drug Paxil for anxiety


and suffered from obstructive sleep apnea. All those factors, which were
present on the day of Marie Basham’s death, inhibited his ability to get
oxygen
to his brain. A lack of oxygen can trigger delirium, she said, especially in
the elderly."

Congratulations are in order for Dr. Ross for being able to understand the
real reason for Autry Basham's delirium was lack of oxygen!!! I wish more
doctors would work a little harder to see what is actually happening in these
cases to produce such out of character behavior rather than following the old
school where the drugs involved were very different. Perhaps lack of oxygen
leading to delirium is an easier conclusion to arrive at in an elderly patient,
but it does happen in all age groups and is a huge contributing factor in
these tragic cases. It is also another reason why hyperbaric oxygen treatment
is
so very helpful after using these drugs and subsequently suffering from
elevated serotonin levels.

There should be grave concern in our country about such tragic cases as this
one where a couple has had a long and loving marriage relationship and in an
instant it is ended in such horror because of what we call "medication"! For
those of you who are younger and sadly may not be aware, things like this
DID NOT HAPPEN in the world we grew up in!!!! Cases like this (which I now see
far too often) were basically non-existent before the widespread use of
serotonergic drugs.

As it states on the front cover of my book, these drugs have literally
turned our world upside down! For this we owe the younger generation and those
generations to come our deepest apologies for the extensive damage we have
allowed to occur. I fear we have left you a terrible, terrible legacy that at
this
point I do not know if we can make restitution for it.


Ann Blake-Tracy, PhD, Executive Director,
International Coalition for Drug Awareness
_www.drugawareness.org_ (http://www.drugawareness.org/) &
_www.ssristories.org_ (http://www.ssristories.org/)
Author of Prozac: Panacea or Pandora? - Our
Serotonin Nightmare & the audio, Help! I Can't
Get Off My Antidepressant!!! (800-280-0730)

E-mail: _atracyphd1@..._ (mailto:atracyphd1@...)


_http://www.nwanews.com/adg/News/241972/
_ (http://www.nwanews.com/adg/News/241972/)

SEBASTIAN COUNTY : Sides dispute delirium led to husband’s killing of wife
BY DAVE HUGHES

Posted on Thursday, October 30, 2008


GREENWOOD ­ A Fayetteville psychiatrist said Wednesday that 85-year-old
Autry Basham suffered from delirium brought on by pneumonia and a sleep
disorder when he slashed the throat of his 83-year-old wife last year.

The testimony of Dr. Robin Ross in Sebastian County Circuit Court in Basham’
s first degree murder trial bolstered the defense’s contention that Basham of
Mansfield is innocent of murder because of a mental disease or defect at the
time he killed his wife of 64 years, Lola Marie Basham, on Aug. 27, 2007.

The jury trial before Circuit Judge James Cox began Monday and is expected
to wrap up today.

Ross testified that in an attempt to explain how Basham, who never had a
reputation for violence and always got along with his wife, could have
committed
such a bizarre act, she concluded that Basham suffered from delirium.

She said tension and anxiety Basham may have been feeling over the falling
out between his wife and son Jerry Basham didn’t play a role in triggering
the
delirium.

Prosecutors have told jurors they believe Basham killed his wife after they
argued the weekend before about her failing memory and her belief that their
son didn’t pay as much attention to them as he should, given the financial
and other help they gave him over the years.

Ross pointed out that Autry Basham had pneumonia, took the drug Paxil for
anxiety and suffered from obstructive sleep apnea. All those factors, which
were present on the day of Marie Basham’s death, inhibited his ability to get
oxygen to his brain. A lack of oxygen can trigger delirium, she said,
especially in the elderly.

Delirium was defined as a disruption of consciousness and a change in
perception that can come on rapidly and can come and go over time. It would
have
been possible for Basham, she said, to be delirious and still carry out a
sequence of events in killing his wife.

In rebuttal, the prosecution called Little Rock forensic psychiatrist
Raymond Molden who testified there was no direct evidence that Basham suffered
from
delirium.

He said the fact that Basham called his son and daughter-in-law before
killing his wife and then carried out the series of actions in killing his wife
showed that he took steps in a logical sequence to bring about a result.

Following a logical sequence of steps, he said, was inconsistent with a
person suffering from delirium.

Paul Deyoub, a forensic psychologist with the Arkansas State Hospital in
Little Rock, testified for the state that he didn’t believe Basham was
delirious
when he killed his wife.

He said he didn’t believe Basham’s contention that he didn’t remember
anything about the killing, and that his first memory that day was waking up in
the hospital. He said nearly all defendants charged with domestic homicide that
he has evaluated claim to have no memory or some loss of memory of the
crime.


**************Get movies delivered to your mailbox. One month free from
blockbuster.com
(http://pr.atwola.com/promoclk/100000075x1212639737x1200784900/aol?redir=https:/\
/www.blockbuster.com/signup/y/reg/p.26978/r.email_footer)


[Non-text portions of this message have been removed]